In late 2025, the Centers for Medicare & Medicaid Services (CMS) through its Innovation Center (CMMI) announced two voluntary Medicaid prescription drug innovation models that will launch in 2026. CMS is negotiating lower prices for certain prescriptions drugs directly with manufacturers and is using the models to engage state Medicaid programs as key purchasers. 

The GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) Model aims to provide participating state Medicaid agencies with most favored nation equivalent drug prices through additional rebates from participating drug manufacturers. The BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model seeks to ensure consistent coverage of GLP-1 therapies across participating Medicaid programs through lower prices and complementary lifestyle and nutrition support programs for eligible beneficiaries. 

Although details on the federally negotiated prices are not yet available, this webinar will include representatives from CMMI to provide a detailed overview of each model’s structure, policy goals, and implementation timeline. There will also be a moderated Q&A session for state participants to ask questions and engage directly with CMMI.

Please note this is a state-only call, therefore only current state government employees directly employed by the state will be approved to attend.